| ²é¿´: 1810 | »Ø¸´: 4 | ||
boronͳæ (СÓÐÃûÆø)
|
[ÇóÖú]
Çó½Ì»ùÒòdefeciencyÊÇʲôÒâ˼
|
| ¿´ÎÄÏ×µÄʱºò£¬ÀïÃæÌáµ½»ùÒòÇóýµÄ¹ûÓ¬£¬·Ö×éÀïÃæÓÐwt(+/+)£¬heterozygous knockout(+/-), heterozygous deficiency(Def/+), homozygous KO(-/-), trans-heterozygous(Def/-)¡£°ïæ˵˵Õâ¸ödefeciencyÊÇʲôÒâ˼£¬¸úknockoutÓÐÊ²Ã´Çø±ð£¿Ð»Ð»À² |
» ²ÂÄãϲ»¶
Wnt-C59£ºPORCN°ÐÏò»¯Ñ§Ì½Õ룬WntÐźÅͨ·×è¶Ï»úÖÆÓë¿ÆÑÐÓ¦ÓÃÈ«½âÎö
ÒѾÓÐ0È˻ظ´
Fexaramine£º³¦µÀÏÞÖÆÐÔFXR»¯Ñ§Ì½Õ룬½á¹¹ÌØÕ÷ÓëÐźÅͨ·Ñо¿È«½âÎö
ÒѾÓÐ0È˻ظ´
»¯Ñ§¹¤³Ì¼°¹¤Òµ»¯Ñ§ÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ188È˻ظ´
NVS-STG2£º°ÐÏòSTING¿çĤÓòµÄ·Ö×Ó½ºÀ༤¶¯¼Á£¬½á¹¹ÌØÕ÷Óë¹Ñ¾Û»¯»úÖÆÑо¿È«½âÎö
ÒѾÓÐ0È˻ظ´
DOTA-GPC3ëÄ£¨CAS 3066439-94-6£©£ºË«¹¦ÄÜ·Ö×Ó̽ÕëǰÌåµÄ½á¹¹ÌØÕ÷Óë±ê¼ÇÓ¦ÓýâÎö
ÒѾÓÐ0È˻ظ´
¿ÆÑÐÓà TLR7/8 Ë«¼¤¶¯¼ÁÔõôѡ£¿ÏÖ»õÓëÖÊ¿ØÒªµã
ÒѾÓÐ0È˻ظ´
SEL120-34A HCl£ºCDK8/CDK19¸ßÑ¡ÔñÐÔ¼¤Ã¸ÒÖÖÆ¼Á
ÒѾÓÐ0È˻ظ´
ÇâÑõ»¯¼Ø»î»¯²Ù×÷
ÒѾÓÐ18È˻ظ´
É¢½ð
ÒѾÓÐ68È˻ظ´
ÉúÎïÖʳ¬¼¶µçÈÝÆ÷
ÒѾÓÐ0È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
»ùÒò²âÐò·ÖÎö΢ÉúÎï¾úȺ½á¹¹ NAÊÇʲôÒâ˼£¿£¿Î´¼ì³ö£¿£¿
ÒѾÓÐ4È˻ظ´
Çó½Ì¾³£¿´Ó¢ÎÄÎÄÏ׵ĴóÉñ£¬ÕâЩÊÇɶÒâË¼ÄØ£¿
ÒѾÓÐ7È˻ظ´
dope ÊÇʲôÒâ˼[Ag-doped Graphene]
ÒѾÓÐ7È˻ظ´
digestÊÇʲôÒâ˼£¿
ÒѾÓÐ14È˻ظ´
ÿ´ÎÅÄTEM¶¼ÊÇÕâÖÖÐÄÇ飬²»ÖªµÀ´ó¼ÒÊÇʲôÑù£¡
ÒѾÓÐ66È˻ظ´
ÎÙÌõºÍÎÙ½ðµÄÇø±ðÊÇʲô
ÒѾÓÐ13È˻ظ´
»ùÒò×éÉÏsnpλµã·Ö²¼µÄËæ»úÐÔÈçºÎ¼ìÑ飿
ÒѾÓÐ3È˻ظ´
radical sinks ʲôÒâ˼£¿
ÒѾÓÐ10È˻ظ´
graphenizationÊÇʲôÒâ˼£¿
ÒѾÓÐ7È˻ظ´
¡¾ÇóÖú/½»Á÷¡¿»ùÒòÇóýÊÔÑé
ÒѾÓÐ23È˻ظ´
¡¾ÇóÖú¡¿smearingÊÇʲôÒâ˼£¿
ÒѾÓÐ5È˻ظ´
¡¾ÇóÖú/½»Á÷¡¿ÇëÎÊÔÚspssÖÐF1,388 = 902110,ÊÇʲôÒâ˼£¡
ÒѾÓÐ3È˻ظ´
¡¾ÇóÖú¡¿metamaterialsÊÇʲôÒâ˼£¿
ÒѾÓÐ12È˻ظ´
¡¾ÇóÖú/½»Á÷¡¿immunoproteasomeÊÇʲôÒâ˼£¿
ÒѾÓÐ4È˻ظ´
¡¾ÇóÖú¡¿A/0Íѵª¹¤ÒÕÖлìºÏÒº»ØÁ÷±È200%ÊÇʲôÒâ˼?
ÒѾÓÐ8È˻ظ´
Î÷¹Ï
ÈÙÓþ°æÖ÷ (ÖªÃû×÷¼Ò)
- MolEPI: 50
- Ó¦Öú: 94 (³õÖÐÉú)
- ¹ó±ö: 3.157
- ½ð±Ò: 1849.6
- É¢½ð: 11458
- ºì»¨: 116
- ɳ·¢: 21
- Ìû×Ó: 7553
- ÔÚÏß: 1449.5Сʱ
- ³æºÅ: 271749
- ×¢²á: 2006-08-13
- ÐÔ±ð: GG
- רҵ: ϸ°ûË¥ÀÏ
- ¹ÜϽ: ·Ö×ÓÉúÎï
2Â¥2012-03-28 10:35:18
boron
ͳæ (СÓÐÃûÆø)
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 817.7
- Ìû×Ó: 159
- ÔÚÏß: 21.2Сʱ
- ³æºÅ: 79511
- ×¢²á: 2005-07-10
- ÐÔ±ð: GG
- רҵ: ĤÉúÎﻯѧÓëĤÉúÎïÎïÀíѧ
3Â¥2012-03-31 19:47:24
Î÷¹Ï
ÈÙÓþ°æÖ÷ (ÖªÃû×÷¼Ò)
- MolEPI: 50
- Ó¦Öú: 94 (³õÖÐÉú)
- ¹ó±ö: 3.157
- ½ð±Ò: 1849.6
- É¢½ð: 11458
- ºì»¨: 116
- ɳ·¢: 21
- Ìû×Ó: 7553
- ÔÚÏß: 1449.5Сʱ
- ³æºÅ: 271749
- ×¢²á: 2006-08-13
- ÐÔ±ð: GG
- רҵ: ϸ°ûË¥ÀÏ
- ¹ÜϽ: ·Ö×ÓÉúÎï
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
boron: ½ð±Ò+2, °¦¡£¡£Ã»ÓÐÈËÇå³þÂ𡣡£¡£ËÍÄãÁ½¸ö½ð±Ò£¬Ð»Ð»ÁË 2012-04-06 10:59:15
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
boron: ½ð±Ò+2, °¦¡£¡£Ã»ÓÐÈËÇå³þÂ𡣡£¡£ËÍÄãÁ½¸ö½ð±Ò£¬Ð»Ð»ÁË 2012-04-06 10:59:15
|
ÔÓºÏȱʧµÄÒâ˼¡£ heterozygous deficiency Results The rate of heterozygous deficiency of ¦Á1-ACT was 4.4% in childrenn with childhood asthma, 0% in healthy children and 0.5% in healthy adults. The rate of heterozygous deficiency of ¦Á1-ACT was far higher in the asthmatic children than in healthy adults (Prevalence ratio=8.89, å2MH=5.68, 95% confidence interval 1.47, 53.60, P< 0.05). ½á¹ûÏø´×é¡¢¶ùͯ¶ÔÕÕ×éÒÔ¼°³ÉÈ˶ÔÕÕ×é¦Á1 ACTÔÓºÏȱʧƵÂÊÒÀ´ÎΪ4.4 %¡¢0¡¢0.05 % ,Ïø´×é½Ï³ÉÈ˶ÔÕÕ×éÃ÷ÏÔÔö¸ß[Prevalenceradio(PR)=8.89, 2MH =5.68,95 %ÖÃÐÅÇø¼ä(1.47,53.60) ,P<0.05] ; ¶Ì¾äÀ´Ô´ Study of heterozygous deficiency of ¦Á_1-antichymotrypsin in childhood asthma ¶ùÍ¯Ïø´¦Á_1-¿¹ÃÓµ°°×øÔÓºÏȱʧÑо¿ ¶Ì¾äÀ´Ô´ Besides,the rate of heterozygous deficiency of¦Á 1 -ACT in the asthmatic group in Guangzhou was higher than that in Chongqing(¦Ö 2 =4.054,P<0.05). ¹ãÖÝÊÐÏø´¶ùͯ¦Á1-ACTÔÓºÏȱʧƵÂÊ (14 % )Ã÷ÏÔ¸ßÓÚÖØÇìÊÐÏø´¶ùͯ (4.4 % ) ,¦Ö2 =4.054,P<0.05 ; ¶Ì¾äÀ´Ô´ Analysis on¦Á_1-ACT heterozygous deficiency in asthmatic children in Guangzhou ¹ãÖÝÊкº×åÏø´¶ùͯ¦Á_1-¿¹ÃÓµ°°×øÔÓºÏȱʧ·ÖÎö ¶Ì¾äÀ´Ô´ The children with heterozygous deficiency of ¦Á1-ACT experienced the first onset of asthma in a far younger age and were hospitalized more frequently. And they had a higher positive rate of radioactive sensitizin test (Prevalence ratio=3.91,å2MH=10.190,95% confidence interval 1.69,9.03,P<0.01). ÇÒ¦Á1 ACTÔÓºÏȱʧ»¼¶ùÏø´³õ·¢ÄêÁäÔ硢סԺ´ÎÊý¶à¡¢·ÅÉäÐÔ¹ýÃôÔÎü¸½ÊÔÑéÑôÐÔÂÊÏÔÖøÔö¸ß[PR=3.91, 2MH=10.190,95 %ÖÃÐÅÇø¼ä(1.69,9.03) ,P<0.01]¡£ |
4Â¥2012-04-01 17:21:56

5Â¥2012-04-15 13:23:31









»Ø¸´´ËÂ¥
28